BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,451,487 | -18.3% | 109,468 | -2.0% | 0.31% | -14.0% |
| Q2 2023 | $9,118,071 | +33.2% | 111,700 | +21.1% | 0.36% | +27.4% |
| Q1 2023 | $6,845,734 | -31.2% | 92,273 | -23.1% | 0.28% | -31.0% |
| Q4 2022 | $9,944,771 | +622.2% | 119,990 | +2374.5% | 0.41% | +588.3% |
| Q3 2022 | $1,377,000 | -18.1% | 4,849 | 0.0% | 0.06% | -14.3% |
| Q2 2022 | $1,681,000 | -19.8% | 4,849 | +0.2% | 0.07% | -1.4% |
| Q1 2022 | $2,096,000 | -16.3% | 4,840 | 0.0% | 0.07% | -2.7% |
| Q4 2021 | $2,504,000 | +6.8% | 4,840 | 0.0% | 0.07% | 0.0% |
| Q3 2021 | $2,345,000 | +9.0% | 4,840 | +1.3% | 0.07% | +10.6% |
| Q2 2021 | $2,151,000 | +17.9% | 4,778 | 0.0% | 0.07% | +8.2% |
| Q1 2021 | $1,825,000 | +20.1% | 4,778 | -0.1% | 0.06% | +15.1% |
| Q4 2020 | $1,519,000 | +28.2% | 4,782 | 0.0% | 0.05% | +1.9% |
| Q3 2020 | $1,185,000 | -6.2% | 4,782 | 0.0% | 0.05% | -14.8% |
| Q2 2020 | $1,263,000 | +57.5% | 4,782 | +21.7% | 0.06% | +32.6% |
| Q3 2018 | $802,000 | +14.7% | 3,928 | -16.9% | 0.05% | +4.5% |
| Q2 2018 | $699,000 | -58.8% | 4,724 | -57.9% | 0.04% | -61.1% |
| Q1 2018 | $1,697,000 | -0.5% | 11,234 | -14.7% | 0.11% | +4.6% |
| Q4 2017 | $1,706,000 | -8.5% | 13,169 | -14.6% | 0.11% | -6.9% |
| Q3 2017 | $1,864,000 | -24.4% | 15,418 | -26.6% | 0.12% | -30.1% |
| Q2 2017 | $2,467,000 | +15.8% | 20,995 | +0.2% | 0.17% | +13.7% |
| Q1 2017 | $2,131,000 | +0.3% | 20,962 | +1.5% | 0.15% | -6.4% |
| Q4 2016 | $2,124,000 | +12.9% | 20,651 | +20.2% | 0.16% | +11.4% |
| Q3 2016 | $1,881,000 | +43.8% | 17,179 | +48.1% | 0.14% | +35.9% |
| Q2 2016 | $1,308,000 | -8.0% | 11,598 | -22.9% | 0.10% | -20.2% |
| Q1 2016 | $1,421,000 | +12.2% | 15,034 | +6.9% | 0.13% | +13.2% |
| Q4 2015 | $1,266,000 | -5.6% | 14,062 | -3.1% | 0.11% | -11.6% |
| Q3 2015 | $1,341,000 | -52.1% | 14,506 | -49.0% | 0.13% | -50.2% |
| Q2 2015 | $2,802,000 | -20.4% | 28,457 | -18.9% | 0.26% | -14.5% |
| Q1 2015 | $3,520,000 | +49.7% | 35,099 | +37.9% | 0.30% | +14.8% |
| Q4 2014 | $2,352,000 | – | 25,454 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |